Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 26, 2022; 10(9): 2783-2791
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2783
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2783
Clinical variables | Univariate analysis (PFS) | Multivariate analysis (PFS) | Univariate analysis (OS) | Multivariate analysis (OS) | ||||||||
HR | 95%CI | P value1 | HR | 95%CI | P value1 | HR | 95%CI | P value | HR | 95%CI | P value1 | |
UBQLN4 (low vs high) | 3.026 | 1.524-6.006 | 0.002 | 2.261 | 1.115-4.583 | 0.024 | 4.357 | 1.962-9.679 | 0 | 2.93 | 1.284-6.683 | 0.011 |
Age (≤ 45 vs > 45) | 4.944 | 2.261-10.809 | 0 | 4.331 | 1.953-9.605 | 0 | 7.171 | 2.763-18.611 | 0 | 5.927 | 2.241-15.678 | 0 |
Grade (I/II vs III) | 1.819 | 0.805-4.108 | 0.15 | 2.444 | 0.913-6.542 | 0.075 | ||||||
FIGO stage (I/II vs III) | 2.869 | 1.983-4.151 | 0 | 2.659 | 1.807-3.911 | 0 | 3.372 | 2.234-5.089 | 0 | 3.048 | 1.968-4.72 | 0 |
- Citation: Wang LN, Huang KJ, Wang L, Cheng HY. Overexpression of Ubiquilin4 is associated with poor prognosis in patients with cervical cancer. World J Clin Cases 2022; 10(9): 2783-2791
- URL: https://www.wjgnet.com/2307-8960/full/v10/i9/2783.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i9.2783